Optimizing vaccine-induced CD8+ T-cell immunity: focus on recombinant adenovirus vectors. (September 2011)

• Record Type: Journal Article
• Authors: Bassett, Jennifer D; Swift, Stephanie L; Bramson, Jonathan L
• Is Part Of: Expert review of vaccines. Volume 10:Number 9(2011)
• Page Start: 1307
• Page End: 1319
• Publication Date: 2011-09
• Subjects: antigen-presenting cell -- immunology -- memory CD8+ T cell -- recombinant adenovirus vaccine -- T-cell polyfunctionality -- vaccine optimization; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.11.88
• Languages: English
• ISSNs: 1476-0584

Abstract

Recombinant adenoviruses have emerged as promising viral vectors for CD8 + T-cell vaccines. Our studies have indicated that unlike most acute infections, the CD8 + T-cell memory population elicited by recombinant human adenovirus serotype 5 (rHuAd5) displays a dominant effector memory phenotype. Persistent, low-level transgene expression from the rHuAd5 vector sustains the CD8 + T-cell memory population and a nonhematopoietic cell compartment appears to be involved in long-term presentation of adenoviral antigens. Although we are beginning to learn more about the factors that control the maintenance and functionality of memory CD8 + T cells, we do not yet fully understand what comprises a protective CD8 + T-cell response. Results from upcoming Phase II clinical trials will be important for determining whether rHuAd5 T-cell vaccines are effective in humans and should help identify correlates of CD8 + T-cell protection.